In Central America, New Adherence Promoters Keep HIV Clients on Treatment

March 02, 2018Carlos considered dropping out of everything. Then he met Aracely, an adherence promoter.Carlos* remembers the exact date he found out he was HIV-positive. He was 20 years old.“January 20, 2015. I was walking with some friends and, over in the square, we saw a tent where they were giving HIV tests,” he says. “As a group of nursing assistants, we said, ‘Let’s do this! Why not?’”Carlos sat alone as he waited for his results. He was #45 in the queue that day.“When they told me I needed additional tests because my results were reactive to virus, I felt my world falling apart,” says Carlos. “I put on my best smile when I met back up with my friends, but the only thing I wanted to do was go home and break down.”HIV in GuatemalaApproximately46,000 people are living with HIV in Guatemala. The adult HIV prevalence rate is low at 0.5%, but since 2010, new HIV infections have increased by 167% and AIDS-related deaths have increased by 23%. Stigma and discrimination, limited access to health care, and migration make the Central America region vulnerable to a growing HIV epidemic.Just 36% of people living with HIV in Guatemala are enrolled in antiretroviral treatment (ART) and only about 65% of people on ART are adherent —taking their medication every day, exactly as prescribed—as measured by their viral load. ART adherence is required to suppress viral load and reduce risk of HIV transmission...
Source: IntraHealth International - Category: International Medicine & Public Health Authors: Source Type: news

Related Links:

Publication date: Available online 16 October 2019Source: Journal of Psychiatric ResearchAuthor(s): Aline Ribeiro Borçoi, Suzanny Mendes de Oliveira, Joaquim Gasparini dos Santos, Mayara Mota de Oliveira, Ivana Alece Moreno Arantes, Flávia Vitorino Freitas, Júlia Assis Pinheiro, Juliana Krüger Arpini, Ester Ribeiro Cunha, Anderson Barros Archanjo, Aricia Leone Evangelista Monteiro de Assis, Bruna Pereira Sorroche, Lídia Maria Rebolho Batista Arantes, Elizeu Borloti, Adriana Madeira Álvares-da-SilvaAbstractObjectiveThe aim of this study was to verify determinant factors for depression...
Source: Journal of Psychiatric Research - Category: Psychiatry Source Type: research
This report therefore uses quality assurance data looking into whether sensory processing sensitivity (SPS) affects treatment outcome among patients with OCD. SPS is a personality trait regarding heightened levels of emotional reactivity and deeper cognitive processing of emotional stimuli. Patients received concentrated exposure treatment for obsessive-compulsive disorder (OCD). They were assessed with one of the most widely used questionnaires for measuring SPS, the Highly Sensitive Person Scale (HSPS). Analyses tested whether HSPS scores at pre-treatment affected treatment outcome, and if sensitivity changed from pre-to...
Source: Journal of Obsessive Compulsive and Related Disorders - Category: Psychiatry Source Type: research
In this study, antidepressive efficacy of white ginseng (Panax gingseng Meyer, WG) was evaluated in stressed ovariectomized rats. Female Sprague Dawley rats were ovariectomized and repeatedly restraint stressed for 2 weeks (2h/day). Thirty minutes before restraint stress, rats were administered saline (control), WG 200 mg/kg (p.o.), WG 400 mg/kg (p.o.), or fluoxetine (PC, 10 mg/kg, i.p.). Tail suspension test (TST) and forced swimming test (FST) were performed to assess antidepressant effect of WG. After behavioral tests, levels of serum corticosterone (CORT) and hippocampal 5-HT were measured. Significant decrease of immo...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Source: The Doctors Lounge - Psychiatry - Category: Psychiatry Tags: Cardiology, Psychiatry, Sports Medicine, News, Source Type: news
This article introduces the guideline development and revised recommendations and guidance on PrEP provision in the updated Taiwan PrEP guideline. The Taiwan PrEP guideline writing group searched randomized controlled trials and guidelines published before October 2017 through Medline/PubMed, Cochrane Database, Embase and ClinicalTrials.gov database. Keywords included pre(-)exposure prophylaxis, PrEP, Truvada, tenofovir, HIV, and AIDS. Each selected article was assessed by two authors using the Grading of Recommendations Assessment, Development and Evaluation. External reviewers were invited to independently evaluate the r...
Source: Journal of Microbiology, Immunology and Infection - Category: Microbiology Source Type: research
Publication date: Available online 15 October 2019Source: Progress in Biophysics and Molecular BiologyAuthor(s): Gilla KaplanAbstractTuberculosis incidence is projected to decline at too slow a rate to meet the targets set at the UN high level meeting on ending tuberculosis, convened in New York in 2018. To understand the causes of the slow progress in tuberculosis control, the Bill and Melinda Gates Foundation supported a patient-pathway analysis that identified significant gaps with patients being “lost” at all points along the care cascade. Although each country differed in the reasons for failure, some comm...
Source: Progress in Biophysics and Molecular Biology - Category: Molecular Biology Source Type: research
Publication date: Available online 15 October 2019Source: Molecular and Cellular ProbesAuthor(s): Danning Lou, Jun Wang, Xiaohang WangAbstractMajor depressive disorder (MDD) is one of the most prevalent psychiatric disorders worldwide and a major public health concern that is associated with grave consequences. Systemic complexity and feedback processes among diverse drivers of the depression disorder contribute to the considerable variation in responses to the treatment of depression. Dysfunctional microRNA (miRNA) is involved in MDD. miR-124 is enriched in the brain and may be critical in neuronal differentiation. Previo...
Source: Molecular and Cellular Probes - Category: Molecular Biology Source Type: research
President Donald Trump’s proposed 2020 budget includes nearly $300 million meant to “defeat the HIV/AIDS epidemic” in the U.S. — even as it calls for a 12% reduction in total funding to the Department of Health and Human Services (HHS). During his February State of the Union address, Trump announced an ambitious plan to “eliminate the HIV epidemic in the United States within 10 years.” During a subsequent call with reporters, health officials said the initiative would focus on 48 at-risk counties across the country and would involve promoting early HIV treatment and diagnosis, expanding ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized HIV/AIDS Source Type: news
On February 8, the day before the White House sent its Fiscal Year (FY) 2017 budget request to Congress, President Obama requested $1.8 billion in emergency funding to respond to the Zika virus at home and abroad. The World Health Organization (WHO) has proclaimed Zika a “public health emergency of international concern,” and governments have been in panic mode. But while there is certainly sufficient cause for alarm, let us not forget another grave threat to public health, which kills 4,400 people every single day and receives relatively little focus: Tuberculosis (TB). TB has now surpassed HIV/AIDS as the lea...
Source: Health Affairs Blog - Category: Health Management Authors: Tags: Costs and Spending Featured Global Health Public Health 2017 budget infectious disease Obama TB tuberculosis USAID WHO Source Type: blogs
00:00 to 02.26—Dr. Bihari gives his background and credentials. Dr. Bihari: My medical training started at Harvard Medical School. I graduated in 1957. Then I trained in Internal Medicine at one of the Harvard teaching hospitals in Boston, Beth Israel, and then in Neurology at Massachusetts General in Boston. Then I went to the National Institutes of Health for two years doing brain physiology—brain research. I did another residency training in Psychiatry in New York, at Columbia Presbyterian Medical Center and then, over the following five or six years, I got very involved in working in Drug Addiction. By 197...
Source: HONEST MEDICINE: My Dream for the Future - Category: Consumer Health News Authors: Tags: Anecdotal Treatments HONEST MEDICINE Integrative Medicine Low Dose Naltrexone Obituaries Source Type: blogs
More News: Budgets | Depression | Education | Epidemics | Epidemiology | Guatemala Health | Health Management | HIV AIDS | Hospitals | Intensive Care | International Medicine & Public Health | Nurses | Nursing | Panama Health | Reclast | Tuberculosis | Universities & Medical Training | Zometa